<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>80</patient-age><report-id>US-CELGENEUS-163-21880-13013361</report-id><gender>female</gender><reactions><reaction>PASSED AWAY</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>REVLIMID</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10028228</indication></indications><outcomes><outcome>Death</outcome></outcomes><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289237</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125102355</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">US-CELGENEUS-163-21880-13013361</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>2013-01-25</transmissiondate>
    <reporttype>1</reporttype>
    <serious code="1">Yes</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>2013-01-21</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>2013-01-21</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">US-CELGENEUS-163-21880-13013361</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <linkedreport>
      <linkreportnumb>US-CELGENE-163-21880-12120279</linkreportnumb>
    </linkedreport>
    <primarysource>
      <reportertitle>Dr.</reportertitle>
      <reportergivename>Myo</reportergivename>
      <reporterfamilyname>Min</reporterfamilyname>
      <reporterstreet>602 South Atwood Rd.</reporterstreet>
      <reportercity>Bel Air</reportercity>
      <reporterstate>MD</reporterstate>
      <reporterpostcode>21014</reporterpostcode>
      <reportercountry>US</reportercountry>
      <qualification code="1">Physician</qualification>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>C-D</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19320401</patientbirthdate>
      <patientsex code="2">Female</patientsex>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10013661</patientepisodename>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10040539</patientepisodename>
      </medicalhistoryepisode>
      <patientdeath>
        <patientdeathdateformat>602</patientdeathdateformat>
        <patientdeathdate>2013</patientdeathdate>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10063378</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">PASSED AWAY</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10011906</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10011906</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionstartdateformat>610</reactionstartdateformat>
        <reactionstartdate>201301</reactionstartdate>
        <reactionfirsttime>4</reactionfirsttime>
        <reactionfirsttimeunit>802</reactionfirsttimeunit>
        <reactionoutcome code="5">fatal</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization code="1">suspsect</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugseparatedosagenumb>21</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>28</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
        <drugdosagetext lang="en">10 Milligram</drugdosagetext>
        <drugdosageform normalized="capsule">Capsules</drugdosageform>
        <drugadministrationroute code="048">Oral</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10028228</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>2012-09-06</drugstartdate>
        <drugstartperiod>4</drugstartperiod>
        <drugstartperiodunit>802</drugstartperiodunit>
        <actiondrug code="6">Not Applicable</actiondrug>
        <drugrecurreadministration code="3">Unknown</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10011906</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Unknown</drugresult>
        </drugreactionrelatedness>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical>PASSED AWAY(USA) <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">Initial </Semaphore>information was received on 21Jan2013 via a <Semaphore x="2472604" class="Procedure" value="Routine Histology Staining Method" score="1.00" ID="C23043">contract </Semaphore><Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacy </Semaphore>from the prescriber' office regarding an <Semaphore x="1387834" class="Patient Age" value="80" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="80" score="1.00" ID="">80 </Semaphore>year old </Semaphore>female who received <Semaphore x="1131427" class="Medicine" value="Revlimid" score="0.74" ID="256603">Revlimid </Semaphore><Semaphore x="4859317408759809" class="Medicine - Revlimid - Dose" value="10 mg" score="0.49" ID="">10 mg </Semaphore><Semaphore x="4859377538301953" class="Medicine - Revlimid - Frequency" value="PO" score="0.49" ID="">PO </Semaphore>daily for 21 days every 4 weeks from 06Sep2012 for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">multiple myeloma</Semaphore>. Lot number was A0160A and expiration date was 31Dec2014. Relevant medical history included <Semaphore x="1470824" class="Disease or Finding" value="Allergic Reaction" score="1.00" ID="C114476">allergy </Semaphore>to <Semaphore x="2609399" class="Disease or Finding" value="Tetanus" score="1.00" ID="C85185">tetanus </Semaphore>toxoid and scallops. Concomitant medications were not reported.The patient was reported to have passed away last week (Jan2013). The date <Semaphore x="1728496" class="Disease or Finding" value="Cause of Death" score="1.00" ID="C81239">of <Semaphore x="2895537" class="MedDRA LLT" value="Death" score="1.00" ID="10011906">death </Semaphore>and cause of <Semaphore x="2895537" class="MedDRA LLT" value="Death" score="1.00" ID="10011906">death </Semaphore></Semaphore>were <Semaphore x="2665498" class="AnatomicStructure" value="Unspecified Anatomic Sites" score="1.00" ID="C13411">not specified</Semaphore>. The reporter causally assessed the patient's <Semaphore x="1837270" class="Disease or Finding" value="Death" score="1.00" ID="C28554">death </Semaphore>to <Semaphore x="1131427" class="Medicine" value="Revlimid" score="0.74" ID="256603">Revlimid </Semaphore>as unknown. Additional information will be requested from the prescriber.Cross reference this case to 163-21880-12120279 (<Semaphore x="1524787" class="Disease or Finding" value="Anemia" score="1.00" ID="C2869">anemia</Semaphore>).</narrativeincludeclinical>
        <sendercomment lang="en">The temporal relationship between therapy and PASSED AWAY suggests that a causal relationship is possible, but underlying disease could provide an alternative explanation.  Incomplete information does not permit a meaningful causality assessment.  Additional information will be requested from the prescriber to assist in providing a relevant causality assessment of the event.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr></original></faers>